{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif
PARP-OC Survey
  1. In your clinical practice, what is the average number of newly diagnosed advanced ovarian cancer patients do you see per month? *
  2. In your clinical practice, what is percentage-wise split of ovarian cancer patients in following stages? *
    3. Stage I
    %
    Stage II
    %
    Stage III
    %
    Stage IV
    %
  3. After first line chemotherapy in the treatment of advanced ovarian cancer patients, approximately what % of patients will have Complete/Partial response? *
    4. %
  4. After second line chemotherapy in the treatment of platinum sensitive relapsed ovarian cancer patients, approximately what % of patients will have Complete/Partial response? *
    5. %
  5. In your clinical practice, what % of ovarian cancer patients are currently undergoing BRCAm/HRD testing: *
    6. %
  6. Which of the following type of BRCA testing do you recommend/prefer in ovarian cancer patients? *

  7. As per your clinical practice, which of the following approach you routinely practice for genetic testing in newly diagnosed ovarian cancer patients? *

  8. In your practice, what % of your newly diagnosed advanced ovarian cancer patients are likely to have *
    9. Germline or somatic BRCA mutation:
    %
    HRD mutation:
    %
    Wild type / no mutation detected by any test method:
    %
  9. In your clinical practice, which PARPi do you prefer for newly diagnosed advanced ovarian cancer patients harboring BRCA mutation (Please tick as appropriate) *
    10. Molecule If cost is not a factor If cost is a factor
    Olaparib

    Rucaparib

  10. In your clinical practice, which PARPi do you prefer for newly diagnosed advanced ovarian cancer patients harboring BRCA wild, HRD positive (Please tick) *
    11. Single Agent/combination If cost is not a concern If cost is a concern
    Olaparib single agent

    Olaparib + Bevacizumab

    Rucaparib

  11. Niraparib in 1st line maintenance has shown improved PFS benefit in patients without BRCA or HRD mutation (HR 0.68). Will you consider using Niraparib in this group of patients upon availability in India, if cost is not a barrier? (Please tick)

  12. As per your clinical practice, what is the average treatment duration of Olaparib in *
    13. 1st line maintenance BRCAm newly diagnosed ovarian cancer
    Months
    1st line maintenance HRD+ve newly diagnosed ovarian cancer
    Months
  13. As per your clinical practice, what is the average treatment duration of Olaparib in 2nd line maintenance for non-gBRCA mutated platinum sensitive relapsed ovarian cancer? *
    14. Months
  14. As per your clinical practice, what is the average starting dose of PARPi for the management of advanced ovarian cancer (newly diagnosed or platinum sensitive relapsed ovarian cancer) *
    15. Olaparib
    mg daily
    Rucaparib
    mg daily
    {{--
  15. On the basis of your clinical experience, what are the major AEs, you have come across with these PARPi in ovarian cancer patients *
    16. Olaparib
    Rucaparib
  16. What % of your ovarian cancer patient have developed AML/MDS on treatment with *
    17. Olaparib
    %
    Rucaparib
    %
    --}}
  17. Considering the fact that Olaparib is available in generics, would you recommend BRCA/ HRD testing at the time of diagnosis in ovarian cancer patients? *

  18. In India, olaparib is approved for platinum sensitive recurrent ovarian cancer (PSROC) irrespective of the BRCA mutation status, In which of the patients set would you prescribe Olaparib? *

  19. In your clinical practice, do you prescribe Olaparib in 3L and beyond in platinum sensitive relapsed ovarian cancer patients? *

  20. While treating advanced ovarian cancer patients, which of the following guidelines do you refer/follow most of the times? *